Partnership Opportunities
Explore Other Related Events
The Gene Therapy Event Series spans in-depth content for each role and specification in gene therapy drug development, so you can curate your event calendar to meet industry leaders most relevant to your area of expertise across the year. Download our Partnership Prospectus now to find out more.
Looking to Position Yourself as a Leader in the Gene Editing Field?
As the only event uniting analytical development drug developers in the gene editing field, this is your opportunity to establish brand excellence and forge relationships with decision makers from both established large companies, and new entrants to the field.
More and more companies are entering the space and require tried and trusted expertise to outsource to, and source provisions from, with our audience telling us they seek expert solutions in the following analytical domains:
Instrument Providers
Highly sensitive and specific analytical instruments (e.g., PCR, LC-MS)
Sequencing
Widely applicable sequencing platforms (e.g. Sanger sequencing, NGS)
Assay Providers
Validated nonclinical, clinical, and CMC assays and bioassays
In return, we can provide you with a unique platform to showcase your capabilities, helping you establish a new network of potential clients and establish an edge over your competitors.
If you work to support gene editing analytical development figures and are looking to establish yourself as a market leader, this is the one meeting in 2025 you should partner with.
Get in touch to explore how we can position your brand in front of 50+ Analytical Development, CMC & QC experts in 2025
Who Has Attended This Meeting in the Past?
Who is This Event Designed For?
*Data from 2023 CRISPR-Based Therapy Analytical Development Summit*
“As a first meeting, it really set up the tone for the future meetings, great to have a specific meeting for CRISPR analytical assays as we move these products from Research to Clinic”
Editas Medicine
“I really enjoyed the focus on assay development, HPLC and MS based method development, and challenges facing the industry around critical starting material characterization”
Vor Biopharma
“The opportunity to network with peers in the field was great”
ReCode Therapeutics
